AMGN:NASDAQAmgen Inc. Analysis
Data as of 2026-09-11 - not real-time
$377.35
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Amgen Inc. is priced at $377.35 and its moving averages line up in bullish order, the shorter sitting above the longer. The last 30 days have lost 2.7%. Momentum indicators put RSI at 31.5 (approaching oversold) with MACD reading bearish. Recent trading has carved out support near $377.22 and resistance around $447.03.
On valuation the read is fair — earnings multiple of 23.4 versus a 29.5 sector average, below the peer group. Revenue is growing at 9.5% on a 23.0% profit margin. The 2.64% dividend yield looks covered by current payout levels.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 40.9%, a beta of 0.53 and a maximum drawdown of 16.6%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — buy in the near term, hold further out, at 3/10 long-term conviction.
On valuation the read is fair — earnings multiple of 23.4 versus a 29.5 sector average, below the peer group. Revenue is growing at 9.5% on a 23.0% profit margin. The 2.64% dividend yield looks covered by current payout levels.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 40.9%, a beta of 0.53 and a maximum drawdown of 16.6%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — buy in the near term, hold further out, at 3/10 long-term conviction.
Top Market Events
Amgen Inc AMGN delivers 10% revenue growth driven by key products like Repatha and UPLIZNA, while raising full-year...Yahoo Finance1monAmgen Inc AMGN Q2 2026 Earnings Call Highlights: Revenue Surges Past $10 Billion, Guidance .David Moadel Tue, September 8, 2026 at 5:08 PM UTC 0 JHVEPhoto / iStock Editorial via Getty Images Quick Read -...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 359.37
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 23.4 versus sector average of 29.5
- Trading above the 200-day average of 359.37
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 23.4 versus sector average of 29.5
- Profit margin of 23.0% is healthy
- Return on equity of 91.5%
Key Metrics & Analysis
Financial Health
Revenue Growth9.50%
Profit Margin22.95%
P/E Ratio23.4
ROE91.47%
ROA8.67%
Debt/Equity490.28
P/B Ratio17.5
Op. Cash Flow$12.5B
Free Cash Flow$8.6B
Industry P/E29.5
Technical Analysis
TrendBullish
RSI31.5
Support$377.22
Resistance$447.03
MA 20$425.38
MA 50$399.10
MA 200$359.37
MACDBearish
VolumeIncreasing
Fear & Greed Index93.13
Valuation
Fair Value$219.40
Target Price$388.03
Upside/Downside2.83%
GradeFair
TypeBlend
Dividend Yield2.64%
Risk Assessment
Beta0.53
Volatility40.87%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.